ELVN

Enliven Therapeutics, Inc. (ELVN) - 2025 Annual Report Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2025. Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics. The company's primary asset is ELVN-001, a potent, highly selective BCR-ABL tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia (CML). In 2025, the company made a strategic decision to explore alternatives for its second program, ELVN-002 (HER2 inhibitor), and is no longer pursuing its development to prioritize ELVN-001. The company has no products approved for commercial sale and has not generated any revenue.

Key Financial Metrics

Note: The filing text does not provide specific gross margin or operating margin percentages as the company has no revenue.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately $14.7 million (16.5%) year-over-year, driven primarily by higher operating expenses.
• Expense Shift: Research and Development (R&D) expenses increased to $85.9 million from $80.8 million. This was due to a $7.8 million increase in external costs for ELVN-001 and higher internal costs (salaries and stock-based compensation), partially offset by a $12.8 million decrease in ELVN-002 costs following the decision to halt its development.
• General & Administrative (G&A): G&A expenses rose significantly to $33.8 million from $23.8 million, primarily due to a $9.6 million increase in stock-based compensation.
• Liquidity Position: Cash and marketable securities increased by approximately $149 million, bolstered by a $216.2 million net proceeds from a public offering in June 2025 and $38.6 million from an at-the-market sales agreement.
• Leadership Change: Rick Fair joined as President and Chief Executive Officer in December 2025.

Guidance, Outlook, and Risks

• Clinical Outlook: The company plans to initiate ENABLE-2, a pivotal Phase 3 trial for ELVN-001, in the second half of 2026. Recent Phase 1b data (announced Jan 2026) showed encouraging Major Molecular Response (MMR) rates of 38% to 53% across cohorts.
• Capital Runway: Management believes existing cash resources ($462.6 million) are sufficient to fund operations into the first half of 2029.
• Regulatory Strategy: ELVN-001 received Orphan Drug Designation for CML in November 2024. The company is preparing for regulatory interactions with the FDA regarding dose selection and Phase 3 design.
• Key Risks:
  • Development Risk: High probability of failure in clinical trials; early data may not predict Phase 3 success.
  • Competition: Intense competition in CML, including Novartis' asciminib (Scemblix) and other TKIs.
  • Third-Party Reliance: Dependence on contract manufacturing organizations (CMOs) and contract research organizations (CROs), some located in China and Europe, exposing the company to geopolitical and supply chain risks.
  • Regulatory Uncertainty: Potential impacts of new U.S. administration policies, FDA staffing changes, and trade tariffs on clinical trial materials.

Investor Verification Checklist

• Verify the specific enrollment numbers and safety data from the Phase 1b ENABLE trial presented in January 2026 to assess the robustness of the Phase 3 plan.
• Confirm the timeline and regulatory feedback for the ENABLE-2 Phase 3 trial initiation in H2 2026.
• Review the status of strategic alternatives for the ELVN-002 program to understand potential asset monetization or write-off impacts.
• Assess the company's supply chain strategy, specifically regarding CMOs in China and Europe, in light of current U.S. trade policies and tariffs.
• Monitor the burn rate relative to the stated runway into H1 2029, given the anticipated increase in costs for Phase 3 trials.